Bortezomib is effective in primary plasma cell leukemia
- 1 January 2006
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (8), 1670-1673
- https://doi.org/10.1080/10428190500520954
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- PAD combination therapy (PS‐341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myelomaBritish Journal of Haematology, 2005
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Bortezomib is an efficient agent in plasma cell leukemiasInternational Journal of Cancer, 2004
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applicationsBlood, 2003
- Highly Sensitive, Automated Immunoassay for Immunoglobulin Free Light Chains in Serum and UrineClinical Chemistry, 2001
- NONSECRETORY MYELOMA, IMMUNOGLOBULIN D MYELOMA, AND PLASMA CELL LEUKEMIAHematology/Oncology Clinics of North America, 1999
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Prognostic Value of Numerical Chromosome Aberrations in Multiple Myeloma: A FISH Analysis of 15 Different ChromosomesBlood, 1998